...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infection and immunity >A Longitudinal Study of Human Antibody Responses toPlasmodium falciparum Rhoptry-Associated Protein 1 in a Region of Seasonal and Unstable Malaria Transmission
【24h】

A Longitudinal Study of Human Antibody Responses toPlasmodium falciparum Rhoptry-Associated Protein 1 in a Region of Seasonal and Unstable Malaria Transmission

机译：季节性和不稳定疟疾传播地区人类对恶性疟原虫Rhoptry相关蛋白1反应的纵向研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rhoptry-associated protein 1 (RAP1) of Plasmodium falciparum is a nonpolymorphic merozoite antigen that is considered a potential candidate for a malaria vaccine against asexual blood stages. In this longitudinal study, recombinant RAP1 (rRAP1) proteins with antigenicity similar to that of P. falciparum-derived RAP1 were used to analyze antibody responses to RAP1 over a period of 4 years (1991 to 1995) of 53 individuals naturally exposed to P. falciparum malaria. In any 1 year during the study, between 23 and 39% of individuals who had malaria developed immunoglobulin G (IgG) antibodies detectable with at least one rRAP1 protein. However, the anti-RAP1 antibody responses were detected only during or shortly after clinical malarial infections. RAP1 antibody levels declined rapidly (within 1 to 2 months) following drug treatment of the infections. No anti-RAP1 antibodies were usually detected a few months after the end of malaria transmission, during the dry season, or by the start of the next malaria season. Thus, RAP1 IgG responses were very short-lived. The short duration of RAP1 antibody response may explain the apparent lack of response in a surprisingly high proportion of individuals after clinical malarial infections. For some individuals who experienced more than one malarial infection, a higher anti-RAP1 antibody response to subsequent infections than to earlier infections was observed. This suggested secondary responses to RAP1 and thus the development of immunological memory for RAP1.
机译：恶性疟原虫的流变相关蛋白1（RAP1）是一种非多态的裂殖子抗原，被认为是针对无性血液阶段的疟疾疫苗的潜在候选者。在这项纵向研究中，重组RAP1（rRAP1）蛋白具有与 P相似的抗原性。恶性疟原虫来源的RAP1用于分析53名自然暴露于 P的个体在4年（1991年至1995年）中对RAP1的抗体反应。恶性疟疾。在研究的任何1年中，有23％至39％的疟疾个体产生了至少一种rRAP1蛋白可检测到的免疫球蛋白G（IgG）抗体。但是，仅在临床疟疾感染期间或之后不久才检测到抗RAP1抗体反应。感染的药物治疗后，RAP1抗体水平迅速下降（1-2个月内）。在疟疾传播结束后的几个月，干旱季节或下一个疟疾季节开始之前，通常没有检测到抗RAP1抗体。因此，RAP1 IgG反应非常短暂。 RAP1抗体应答的持续时间短可能解释了在临床疟疾感染后，比例高得惊人的人明显缺乏应答。对于某些经历了一种以上疟疾感染的个体，观察到对后续感染的抗RAP1抗体反应要比对早期感染的反应高。这表明对RAP1有继发性反应，因此提示了RAP1的免疫记忆发育。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号